Cough
Cough is a vital protective reflex of the respiratory system, serving to clear irritants, mucus, and foreign particles from the airways. While often a temporary symptom of acute infections, it can persist as a chronic condition, significantly impacting quality of life and imposing a substantial health burden. Chronic cough is a common symptom, with prevalence estimates varying from 1% to 10%. [1]
Biological Basis
The biological basis of cough involves complex neuronal pathways and a highly sensitive cough reflex. Research indicates that both chronic dry cough and angiotensin-converting enzyme inhibitor (ACEi)-induced cough share similar clinical manifestations, including a dry nature and involvement of cough reflex hypersensitivity, suggesting a central role for the nervous system in their pathophysiology. [1] Genetic studies have begun to unravel these mechanisms, with findings implicating neuronal excitability and the bradykinin pathway in ACEi-induced cough. [1] For instance, variants in the KCNIP4 gene, which encodes a potassium channel interacting protein, have been associated with ACEi-induced cough. Although KCNIP4 is predominantly expressed in brain and spinal cord structures, these genetic variants likely play a regulatory role, possibly related to mRNA splicing or expression, influencing the sensitivity of sensory nerve afferents in the lung. [2] Genetic variation can also influence outcomes such as coughing/wheezing and forced vital capacity (FVC), with links to lung and ciliary function. [3]
Clinical Relevance
Clinically, cough can manifest in various forms, including acute cough and chronic cough, which is further categorized into conditions like refractory chronic cough, unexplained chronic cough, and cough hypersensitivity syndrome. [1] Angiotensin-converting enzyme (ACE) inhibitor-induced cough is a well-recognized side effect of certain medications, with a higher prevalence observed among women and East Asian populations. [2] Studies have identified several comorbidities that can contribute to the risk of cough, including asthma, postnasal drip, gastroesophageal reflux disease (GERD), bronchitis, emphysema, bronchiectasis, allergic alveolitis, and chronic obstructive pulmonary disease (COPD). [2] Genetic research reveals significant correlations between chronic dry cough and conditions like multi-site chronic pain and asthma. Similarly, ACEi-induced cough shows genetic correlations with asthma and type 2 diabetes. [1] Understanding these genetic underpinnings is crucial for guiding mechanistic studies and drug development, potentially increasing the success rate of new therapies. [1]
Social Importance
The pervasive nature of cough, particularly its chronic forms, underscores its significant social importance. It affects daily activities, sleep, and overall well-being for millions globally. The challenges in accurately diagnosing and categorizing chronic cough, partly due to poor coding in electronic health records, highlight the need for deeper understanding of its biological basis. [1] Genomic studies, such as genome-wide association studies (GWAS), are instrumental in identifying associated genetic variants and implicating relevant genes, thereby shedding light on the molecular basis of chronic dry cough and ACEi-induced cough. These efforts provide genetic evidence that can inform future therapeutic developments and improve patient care. [1] Furthermore, initiatives to boost underrepresented populations in GWAS are essential to ensure the generalizability of findings across diverse ancestries. [1]
Challenges in Phenotype Definition and Data Ascertainment
The precise characterization of cough phenotypes presents significant challenges, particularly when relying on electronic medical record (EMR) data, which are often incomplete and collected unsystematically. This can lead to misclassification, such as inappropriately assigning individuals who discontinued ACE inhibitor therapy due to cough to a control group, thereby weakening or skewing associations. [2] Furthermore, detailed clinical information regarding ACE inhibitor dosage, treatment duration, and indication is frequently unavailable for systematic extraction, preventing a comprehensive evaluation of these factors' contributions to ACE inhibitor-induced cough. [2] The inability to incorporate rigorous phenotype definitions, such as assessing the effect of ACE inhibitor cessation on cough at fixed time intervals, stems from these protocols not being standard in routine clinical practice. [2]
Moreover, the varied terminology used to describe and categorize chronic cough, including cough hypersensitivity syndrome, refractory chronic cough, and unexplained chronic cough, were not distinguished in some studies, typically requiring specialist clinical assessment. [1] This issue is compounded by the poor coding of cough in EMRs and its limited characterization in questionnaires. [1] Such misclassification, while a potential limitation, generally tends to reduce effect size estimates towards the null, potentially obscuring true associations. [1] Additionally, a study on pharmacogenomics and placebo response was not specifically designed to examine subjective outcomes like coughing, limiting the interpretability of self-reported symptoms. [4]
Statistical Power, Replication, and Genetic Complexity
Statistical power limitations are a notable constraint, with studies having limited capacity to detect associations for single nucleotide polymorphisms (SNPs) with minor allele frequencies (MAFs) below 10%, thus impeding the quantification of contributions from low-frequency variants. [2] The practice of imputing across multiple genotyping platforms can introduce systematic frequency differences, potentially leading to an inflated Type I error rate in genome-wide association studies (GWAS). [2] In specific replication sets, observed effect sizes were weaker, likely attributable to lower positive predictive value and specificity in the case definitions utilized. [2]
Small sample sizes within particular ancestral subgroups, such as African Americans, resulted in insufficient power to replicate associations or achieve statistical significance, despite trends in the expected direction. [2] The absence of replication in certain findings further underscores the need for independent validation to confirm initial discoveries. [4] It is also recognized that the genetic architecture of complex traits like cough is likely polygenic, meaning that attributing observed effects to only a few genes may oversimplify the underlying biological mechanisms. [4]
Generalizability and Unaccounted Confounders
A significant limitation is the modest sample sizes for non-European ancestry groups, which restricts the generalizability of findings despite efforts to maximize data availability. [1] The underrepresentation of diverse populations is a pervasive issue in GWAS, highlighting the need for targeted initiatives to enhance population diversity and improve the applicability of research findings across different ancestries. [1] While genetic associations are less susceptible to confounding from environmental, lifestyle, or socioeconomic factors due to the random assignment of genetic variants during gamete formation, these unmeasured confounders can still influence observational study components that contribute to phenotype ascertainment. [1]
Furthermore, observed racial differences in the prevalence of ACE inhibitor-induced cough may not be fully accounted for by variations in the frequencies of associated SNPs, suggesting that other independent or contributing factors play a role in these population differences. [2] Despite advancements in understanding, the complete biological mechanisms underlying chronic cough remain incompletely understood, indicating persistent knowledge gaps that necessitate further research. [1]
Variants
Genetic variations within several genes have been linked to an individual's susceptibility to cough, particularly chronic dry cough and cough induced by angiotensin-converting enzyme inhibitors (ACEi). The rs7761208 variant, located in the PREP gene, is associated with chronic dry cough. [1] PREP encodes prolyl endopeptidase, an enzyme that plays a role in mediating neuropeptide activity; alterations in its function through genetic variants could affect the breakdown of neuropeptides involved in modulating the cough reflex. [1] Similarly, the rs6062847 variant, located in the SLCO4A1 gene (often discussed alongside LINC00686), has been implicated in ACEi-induced cough and is also associated with an increased risk of asthma. [1] SLCO4A1 encodes a solute carrier organic anion transporter, which facilitates the movement of various substances across cell membranes, potentially influencing drug metabolism or inflammatory responses relevant to cough.
The SRBD1 gene, with variants such as rs1544730 (often discussed with LINC01121) and rs3770259, shows a strong association with both chronic dry cough and ACEi-induced cough. [1] Specifically, the rs1544730 locus met a Bonferroni threshold for association with chronic dry cough, indicating a robust genetic link. [1] SRBD1 is involved in RNA binding and processing, and variants could impact gene expression or protein synthesis in pathways relevant to neurological or inflammatory responses associated with cough. Furthermore, variants like rs343240 and rs78598167 in the L3MBTL4 gene have been previously identified in relation to ACEi-induced cough. [1] L3MBTL4 is a chromatin-binding protein that plays a role in gene regulation, and its dysregulation through genetic variants might alter the expression of genes involved in cough pathways. The MAPKAP1 gene, associated with the rs7848821 variant, is also implicated in ACEi-induced cough and plays roles in cell division, repair, and neuronal signaling. [1] Alterations in MAPKAP1 could impact the neurological pathways that mediate the cough reflex.
Other genetic loci also contribute to the complex genetics of cough. The rs6430080 and rs1533426 variants are found in the region of RPL6P5 and METAP2P1, which are pseudogenes often associated with protein synthesis or modification pathways. While pseudogenes are typically non-coding, variants within these regions can sometimes influence the expression of nearby functional genes or regulatory elements, potentially having subtle effects on cellular processes relevant to conditions like cough. The rs5924943 variant is located near VMA21 and PASD1. VMA21 is broadly involved in cellular homeostasis [1] a fundamental process for maintaining cellular balance, which could indirectly affect the body's response to irritants or inflammation that trigger cough. PASD1 is a protein involved in cell cycle regulation and transcription, and variations might impact cellular proliferation or gene expression. Finally, the rs189601688 variant is linked to the NDUFB4P4 and KIF3C genes. NDUFB4P4 is a pseudogene related to a subunit of mitochondrial complex I, crucial for cellular energy production, while KIF3C encodes a kinesin motor protein, vital for intracellular transport. These genes represent diverse functions, and their identification highlights the varied genetic landscape underlying cough susceptibility. [1]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs6430080 rs1533426 |
RPL6P5 - METAP2P1 | smoking initiation cough |
| rs6062847 | SLCO4A1 - LINC00686 | response to angiotensin-converting enzyme inhibitor cough |
| rs7761208 | PREP | cough |
| rs5924943 | VMA21 - PASD1 | cough |
| rs343240 | L3MBTL4 | cough |
| rs1544730 | LINC01121 - SRBD1 | response to angiotensin-converting enzyme inhibitor cough |
| rs78598167 | L3MBTL4 | cough |
| rs7848821 | MAPKAP1 | cough |
| rs189601688 | NDUFB4P4 - KIF3C | cough |
| rs3770259 | SRBD1 | cough |
Defining Cough and its Phenotypes
Cough, as a clinical phenotype, is defined primarily by its presence and characteristics, particularly when induced or persistent.. [5] A specific and well-studied phenotype is ACE inhibitor-induced cough (ACEi-induced cough), which refers to a cough directly attributable to the use of angiotensin-converting enzyme inhibitors.. [5] Another distinct phenotype is chronic dry cough, characterized by its prolonged duration and typically non-productive nature.. [1] The conceptual framework of "cough hypersensitivity due to neuronal dysfunction" has been established, proposing a common underlying mechanism for chronic dry cough and ACEi-induced cough at a population level.. [1]
The terminology surrounding chronic cough can be variable, encompassing terms such as "cough hypersensitivity syndrome," "refractory chronic cough," and "unexplained chronic cough.". [1] These terms highlight different aspects of chronic cough presentation and are used to categorize the condition, often implying varying degrees of responsiveness to treatment or identifiable causes. Self-report is a common method for assessing cough, sometimes combined with other respiratory symptoms such as wheezing, to form composite measures in clinical studies.. [4]
Classification of Cough
Cough classification extends beyond its duration and character to include its etiology and association with specific medical conditions. ACEi-induced cough represents a classification based on a pharmacological trigger, while chronic dry cough is categorized by its duration and absence of sputum production.. [1] Further classifications are often linked to comorbidities that may contribute to cough risk, such as asthma, postnasal drip, gastroesophageal reflux disease, bronchitis, emphysema, bronchiectasis, allergic alveolitis, and chronic obstructive pulmonary disease.. [5] These associated conditions are typically identified using standardized coding systems like the International Classification of Diseases (ICD-9 codes) or PheCode criteria, which facilitate systematic data collection and analysis in large cohorts.. [5]
The categorization of chronic cough into "cough hypersensitivity syndrome," "refractory chronic cough," and "unexplained chronic cough" reflects a nuanced understanding of its clinical presentation and potential underlying mechanisms.. [1] However, distinguishing between these specific conditions often necessitates specialist clinical assessment, partly due to the challenges associated with comprehensive cough coding in electronic health records and the limited characterization through standard questionnaires.. [1] This emphasizes the need for robust and standardized diagnostic approaches to accurately classify cough subtypes.
Operationalization and Measurement Criteria
Operational definitions for cough phenotypes are critical for consistent diagnosis and research. For ACEi-induced cough, cases in electronic medical records (EMR) are often defined by the co-occurrence of an ACEi drug name or class designator and 'cough' on the same line within the structured 'Allergy' section, indicating a healthcare provider's documentation.. [5] Controls are typically subjects with documented ACEi use over a sustained period (e.g., at least six months) who do not have an associated cough recorded in the Allergy section.. [5] These EMR-based algorithms are developed and refined through iterative processes, including validation against manual EMR review, to achieve high positive predictive values for accurate case and control assignment.. [5]
Measurement approaches for cough can include self-reported frequency, such as "coughing/wheezing frequency," which may be used as a continuous variable in studies assessing changes in respiratory symptoms.. [4] However, EMR data collection can be incomplete or unsystematic, potentially leading to misclassification if, for example, patients are switched from ACEi therapy due to cough before the EMR data capture period.. [5] While some research protocols incorporate specific criteria, such as evaluating the effect of ACEi cessation on cough at a fixed time interval, these are not standard in routine clinical practice, limiting their systematic extraction from EMRs for large-scale studies.. [5] In genetic studies, specific thresholds for significance, such as p<5×10–8 or p<1.0E-05 for genome-wide significance, are applied to identify variants associated with cough phenotypes.. [1]
Neurological Hypersensitivity and Genetic Predisposition
Cough, particularly chronic dry cough, is often rooted in a phenomenon known as cough hypersensitivity, which involves neuronal dysfunction. This mechanism indicates an exaggerated response of the cough reflex due to altered nerve signaling, where the cough reflex is overly sensitive to stimuli. [1] Research at a population level suggests that this neuronal dysfunction broadly applies to chronic dry cough, highlighting its widespread impact as a fundamental underlying cause. [1]
Genetic factors play a significant role in predisposing individuals to this cough hypersensitivity. Studies have identified a clear association between genetic predisposition and the development of chronic dry cough, indicating that inherited variants contribute to an individual's susceptibility. [1] This genetic influence points towards underlying biological processes, particularly those involving neurological pathways, that can be further explored for a deeper understanding of cough mechanisms and potential therapeutic targets. [1]
Medication-Induced Cough and Gene-Environment Interactions
Certain medications can act as environmental triggers that interact with an individual's genetic makeup to induce cough. A prominent example is Angiotensin-Converting Enzyme inhibitor (ACEi)-induced cough, a recognized side effect of a class of drugs used to treat hypertension and heart failure. [1] This specific type of cough is also characterized by the mechanism of cough hypersensitivity due to neuronal dysfunction, similar to chronic dry cough, suggesting a shared neurological basis. [1]
The identification of a genetic predisposition to ACEi-induced cough demonstrates a crucial gene-environment interaction, where an individual's inherited genetic profile influences their reaction to a specific drug. [1] Understanding these interactions is vital for personalized medicine, allowing for the identification of individuals at higher risk for medication side effects and guiding drug discovery efforts to develop safer alternatives. [1]
Associated Comorbidities
The genetic predisposition to cough is not an isolated factor but is often linked with various other health conditions, known as comorbidities. These associations suggest shared biological pathways or underlying vulnerabilities that contribute to the development of multiple traits within an individual. [1] One notable comorbidity identified in relation to genetic predisposition to cough is chronic pain, indicating a potential overlap in the neurological or physiological mechanisms underlying both conditions. [1]
The connection between cough and conditions like chronic pain underscores the complexity of the body's physiological systems and the potential for overlapping neurological or inflammatory mechanisms. Investigating these comorbidities can advance the understanding of the biological processes involved in cough, offering new avenues for research and drug development that consider the broader health context of affected individuals. [1]
The Cough Reflex and Neuronal Hypersensitivity
Chronic dry cough is a prevalent condition that significantly impacts quality of life and healthcare systems, often stemming from various underlying factors such as chronic lung diseases, gastro-oesophageal reflux, rhinitis, or environmental exposures like smoking. [1] It can also manifest as a side effect of medications, notably angiotensin-converting enzyme inhibitors (ACEis), or remain unexplained in some individuals. [1] These diverse etiologies converge on a common physiological response: the cough reflex, which can become hypersensitive, leading to troublesome coughing triggered by minimal stimuli. [1]
Cough hypersensitivity syndrome describes this heightened reflex, characterized by an exaggerated cough response to thermal, mechanical, or chemical exposures. [1] A key underlying mechanism involves neuronal dysfunction and dysregulation within the nervous system, which is believed to drive this hypersensitive state. [1] Both chronic dry cough and ACEi-induced cough exhibit similar clinical features, including their dry nature and evidence of cough reflex hypersensitivity, strongly implicating the nervous system in their pathophysiology. [1] Therapeutic strategies are increasingly focusing on targeting these neuronal mechanisms, demonstrating efficacy in patients with refractory or unexplained chronic cough who present with features of hypersensitivity. [1]
Molecular Regulators of Neuronal Excitability
At a molecular and cellular level, the intricate control of neuronal excitability plays a crucial role in modulating the cough reflex. Key biomolecules such as potassium ion channels are central to this regulation, influencing the electrical activity of neurons. [1] For instance, KCNIP4 and KCNA10 encode subunits of potassium ion channels that directly modulate neuronal excitability, with animal studies highlighting the importance of these channels in smooth muscle reactivity and the overall cough reflex. [1] Variants in KCNIP4 have been specifically associated with ACEi-induced cough, suggesting a direct link between genetic variations affecting these channels and cough susceptibility. [5]
Beyond ion channels, neuropeptides and their receptors are also critical mediators. NTSR1, for example, mediates the activity of neurotensin, a pro-inflammatory peptide involved in the contraction of smooth muscles. [1] NTSR1 also upregulates the secretion of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. [1] Studies have shown that centrally acting agonists of GABAB receptors can inhibit the cough reflex, and drugs like baclofen have been reported to suppress ACEi-induced cough, further underscoring the role of neurotransmitter pathways in cough modulation. [1] Another enzyme, PREP, is implicated in mediating neuropeptide activity, adding another layer to the complex regulatory network governing the cough response. [1] The bradykinin pathway is also a significant molecular player implicated in ACEi-induced cough, contributing to the stimulation of sensory nerve afferents. [1]
Genetic Underpinnings of Cough Susceptibility
Genetic mechanisms provide fundamental insights into the causal relationships underlying chronic cough, offering a robust framework for understanding its biological basis and guiding drug development. [1] While the genetics of conditions like asthma and COPD have been extensively studied, genome-wide association studies (GWAS) for chronic dry cough have historically been limited. [1] Recent research, however, has begun to unravel the genetic architecture of chronic dry cough and ACEi-induced cough, revealing shared genetic determinants and highlighting the contribution of neurobiological processes. [1]
Specific genetic variants, such as single nucleotide polymorphisms (SNPs) within the KCNIP4 gene, have been strongly associated with ACEi-induced cough. [5] These SNPs are located in an intronic region and are thought to exert a regulatory role, likely affecting KCNIP4 mRNA splicing or expression rather than altering the protein's primary structure. [5] The genetic predisposition to cough also shows significant correlations with other comorbidities, including chronic pain and asthma, suggesting shared biological pathways and genetic influences that warrant consideration in drug discovery efforts. [1] The heritability of chronic dry cough and ACEi-induced cough has been estimated, indicating a substantial genetic component to these traits. [1]
Pathophysiological Processes and Systemic Interactions
The pathophysiology of chronic cough often involves a disruption of normal homeostatic mechanisms, particularly within the nervous system. The leading hypothesis for ACEi-induced cough, for instance, centers on the stimulation of sensory nerve afferents within the lung. [5] This stimulation is thought to result from the accumulation of inflammatory mediators that are typically broken down by the angiotensin-converting enzyme, leading to heightened neuronal sensitivity. [5] While KCNIP4 is widely expressed in central and peripheral neuronal structures, its presence in the lung appears to be largely restricted to these sensory nerves, explaining why its expression levels might be low in whole-cell lung homogenates. [5]
This neuronal dysfunction extends beyond the respiratory system, as evidenced by the genetic correlation between chronic dry cough and conditions like chronic pain. [1] Such associations suggest broader systemic consequences and shared underlying biological processes that contribute to both traits. [1] Furthermore, KCNIP4 has been linked to airway hyper-responsiveness in studies of human asthma, indicating that genetic variations influencing neuronal excitability can also impact lung physiology and contribute to conditions characterized by heightened airway reactivity. [5] These interconnections highlight cough not merely as a localized respiratory symptom, but as a complex trait influenced by widespread neuronal and systemic interactions.
Neuronal Excitability and Signal Transduction
The pathophysiology of chronic dry cough, including ACE inhibitor-induced cough, is significantly underpinned by dysregulation in neuronal excitability and signaling pathways. Genes such as KCNA10 and KCNIP4, which encode potassium ion channel subunits, play a critical role in modulating neuronal excitability, with animal studies providing evidence for their involvement in smooth muscle reactivity and the cough reflex. [1] Alterations in these potassium channels can lead to neuronal dysfunction and contribute to cough hypersensitivity. Furthermore, CTNNA1 (catenin alpha 1) is a protein involved in cell-cell adhesion and crucial for synapse morphogenesis and plasticity, indicating its role in the structural and functional integrity of neuronal networks underlying the cough reflex. [1]
Another key signaling pathway involves the neurotensin receptor 1 (NTSR1), which mediates the activity of neurotensin, a pro-inflammatory peptide known to modulate smooth muscle contraction. [1] Activation of NTSR1 also upregulates the secretion of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter. [1] This mechanism highlights a complex interplay where a pro-inflammatory signal can indirectly influence inhibitory neuronal pathways, as centrally acting _GABA_B receptor agonists have been shown to inhibit the cough reflex, including ACEi-induced cough. [1] The enzyme prolyl endopeptidase (PREP) is additionally implicated in mediating neuropeptide activity, further underscoring the role of neurochemical signaling in cough regulation. [1]
Genetic Regulation and Protein Homeostasis
The intricate regulation of gene expression and protein function is central to maintaining the delicate balance required for normal physiological responses, and its perturbation can lead to chronic cough. Genes such as ALX1 function as transcription factors, directly influencing the expression of other genes, while RBM15 is involved in broader gene expression mechanisms. [1] These regulatory proteins can impact the development and function of neuronal pathways or other cellular processes relevant to cough. Furthermore, proteins involved in cellular quality control and transport, like SIL1 (involved in protein processing) and RASSF9 (which plays a role in intracellular and endosomal transport, protein targeting, and signal transduction), ensure the proper folding, localization, and activity of proteins essential for cellular communication and function. [1]
Beyond direct signaling components, the cellular machinery for maintaining general homeostasis and integrity also impacts cough pathophysiology. For instance, ATP23 is an enzyme critical for DNA repair, and CPEB2 is important for cell cycle regulation, both fundamental processes for cellular health. [1] Genes like VMA21 and CYP27B1 are associated with maintaining broader cellular homeostasis. [1] Dysregulation in any of these basic cellular functions, whether in gene expression, protein processing, or general cellular maintenance, can indirectly affect the sensitivity and responsiveness of the cough reflex by impacting the health and function of the relevant sensory nerves or effector cells.
Pathway Crosstalk and Neuroinflammatory Modulation
Cough generation involves significant crosstalk between neuronal and inflammatory pathways, particularly in conditions like ACEi-induced cough and chronic dry cough. A key hypothesized mechanism for ACEi-induced cough involves the stimulation of sensory nerve afferents in the lung due to the accumulation of inflammatory mediators that are normally degraded by the ACE enzyme. [5] This suggests a direct link where inflammatory signals can sensitize or activate neuronal pathways. The neurotensin receptor 1 (NTSR1) exemplifies this crosstalk, as it mediates the activity of neurotensin, a pro-inflammatory peptide that can modulate smooth muscle contraction. [1]
In addition to its pro-inflammatory role, NTSR1 also upregulates the secretion of GABA, an inhibitory neurotransmitter. [1] This dual action demonstrates a complex regulatory feedback loop where a pro-inflammatory signal can trigger an inhibitory neurochemical response. The effectiveness of centrally acting _GABA_B receptor agonists, such as baclofen, in inhibiting the cough reflex and suppressing ACEi-induced cough further highlights the importance of balancing excitatory and inhibitory signals in the nervous system to modulate cough sensitivity. [1] Such interactions underscore how inflammatory stimuli can modulate neuronal function and contribute to cough hypersensitivity.
Systems-Level Dysregulation in Cough Hypersensitivity and Therapeutic Implications
Chronic dry cough and ACEi-induced cough often manifest as cough hypersensitivity, an emergent property resulting from the systems-level dysregulation of interconnected pathways, primarily neurological ones. [1] Genetic associations provide crucial insights into these causal relationships, highlighting a broad contribution of neurobiological processes to chronic cough pathophysiology. [1] For example, variants in genes like KCNA10, KCNIP4, NTSR1, and PREP collectively point to altered neuronal excitability and neuropeptide modulation as central to this hypersensitivity. [1]
The identification of these dysregulated pathways offers significant opportunities for drug development and repurposing. [1] For instance, KCNA10 is a target of an approved drug used for managing multiple sclerosis symptoms, suggesting a potential repurposing for cough. [1] Similarly, the efficacy of _GABA_B receptor agonists in inhibiting cough, including ACEi-induced cough, indicates these receptors as viable therapeutic targets. [1] Furthermore, NTSR1 is a target for a drug currently undergoing trials for small cell lung carcinoma, illustrating how understanding pathway dysregulation in cough can leverage existing drug development efforts for new applications. [1]
Genetic Insights into Cough Pathophysiology and Risk
Genetic studies have significantly advanced the understanding of cough pathophysiology, particularly for chronic dry cough and ACE inhibitor (ACEi)-induced cough. Genome-wide association studies (GWAS) have identified specific genetic variants, such as those in KCNIP4, associated with ACEi-induced cough, implicating neuronal dysfunction and ion channel activity in its development. [5] The genetic overlap and shared clinical manifestations, including cough reflex hypersensitivity, between chronic dry cough and ACEi-induced cough suggest common neurobiological mechanisms. [1] These insights are crucial for diagnostic utility, enabling a deeper understanding of the underlying causes beyond symptomatic presentation. By identifying genetic predispositions, clinicians can better assess an individual's risk for developing these cough phenotypes, moving towards personalized medicine approaches for risk stratification and potentially informing prevention strategies.
Comorbidities and Prognostic Implications
Genetic research has revealed significant associations between cough phenotypes and various comorbidities, shedding light on shared biological pathways and potential prognostic indicators. Both ACEi-induced cough and chronic dry cough exhibit substantial genetic correlations with chronic pain and asthma. [1] Additionally, ACEi-induced cough shows genetic links with type 2 diabetes. [1] These findings expand the established concept of cough hypersensitivity due to neuronal dysfunction, suggesting that a genetic predisposition to cough may coincide with predispositions to other chronic conditions. Such genetic associations can aid in predicting disease progression, identifying individuals with overlapping phenotypes, and understanding the long-term implications for patient care, which should be considered in drug discovery and development efforts.
Guiding Treatment Selection and Monitoring
Pharmacogenomic insights offer promising avenues for optimizing treatment selection and monitoring strategies for cough. Genetic variations can significantly influence a patient's response to therapeutic interventions, as evidenced by studies linking specific genetic signals for coughing and wheezing to lung and ciliary function. [4] For instance, a particular G allele was associated with a greater improvement in coughing/wheezing among patients treated with budesonide, highlighting a significant pharmacogenomic effect that could guide individualized therapeutic choices. [4] Identifying genetic markers that predict treatment efficacy or susceptibility to adverse drug reactions, such as ACEi-induced cough, is vital for personalized medicine. This approach can minimize trial-and-error prescribing, reduce adverse events, and improve patient outcomes through tailored monitoring plans.
Frequently Asked Questions About Cough
These questions address the most important and specific aspects of cough based on current genetic research.
1. Why do some medications make me cough so much?
Yes, certain medications, like ACE inhibitors for blood pressure, can cause a persistent dry cough. This happens because genetic variations, for example in a gene called KCNIP4, can influence how sensitive your cough reflex is, especially through the bradykinin pathway. Women and people of East Asian descent are also more likely to experience this side effect.
2. My cough lasts forever; why am I so prone to it?
Your tendency for a persistent cough might have a genetic component. Research shows that chronic dry cough can be linked to your genes, influencing the sensitivity of your nervous system and cough reflex. This can make you more susceptible to prolonged coughing compared to others.
3. Does my Asian background affect my risk of a chronic cough?
Yes, if you're taking certain blood pressure medications like ACE inhibitors, your East Asian background does put you at a higher risk for developing an ACE inhibitor-induced cough. This suggests genetic factors play a role in how different populations respond to these drugs.
4. I have asthma, does that make my cough worse?
Yes, there's a strong genetic connection between chronic cough and conditions like asthma. If you have asthma, your genetic makeup might make you more prone to developing a persistent cough, as similar underlying genetic pathways can be involved in both conditions.
5. Can my other health issues like pain or diabetes be linked to my cough?
Yes, genetic studies show specific connections. If you have chronic dry cough, it's genetically correlated with multi-site chronic pain. If your cough is from ACE inhibitor medication, it shows genetic links with type 2 diabetes, suggesting shared genetic predispositions.
6. Why does my cough feel like it's "all in my head" sometimes?
Your cough often feels that way because the nervous system plays a central role in its sensitivity. Genetic variations can make your cough reflex hypersensitive, meaning even minor irritations can trigger a strong cough, highlighting a significant neurological component.
7. Do women cough more than men with certain meds?
Yes, if you're a woman taking ACE inhibitor medications, you have a higher likelihood of experiencing a cough as a side effect compared to men. This difference is observed in studies and points to specific biological or genetic predispositions.
8. Why does my chronic cough disrupt my sleep and daily life so much?
A chronic cough can severely impact your quality of life, including sleep and daily activities, because its underlying biological basis, often influenced by your genes, can make your airways highly sensitive. This leads to persistent irritation and the reflex that disrupts well-being.
9. Why do some people just never seem to get a chronic cough?
The difference likely comes down to individual genetic variations influencing their cough reflex sensitivity and underlying neurological pathways. Some people naturally have a less sensitive system, making them less prone to developing a persistent cough.
10. Can my genes affect how my lungs cope with a cough?
Yes, genetic variations can influence outcomes like coughing, wheezing, and even your forced vital capacity (FVC), which is a measure of lung function. These genetic links can affect how well your lungs and cilia function, impacting your cough response.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Coley, K. "Genomics of chronic dry cough unravels neurological pathways." Eur Respir J, vol. 63, no. 4, 2024, p. 2302341.
[2] Mosley, J. D. "A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough." Pharmacogenomics Journal, 2016.
[3] Wang, R. S. "Pharmacogenomics and Placebo Response in a Randomized Clinical Trial in Asthma." Clinical Pharmacology & Therapeutics.
[4] Wang, R. S., et al. "Pharmacogenomics and Placebo Response in a Randomized Clinical Trial in Asthma." Clinical Pharmacology & Therapeutics, 2019.
[5] Mosley, J. D., et al. "A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough." Pharmacogenomics Journal, 2015.